Cargando…

Shared decision-making in advanced kidney disease: a scoping review

OBJECTIVES: To provide a comprehensive overview of interventions that support shared decision-making (SDM) for treatment modality decisions in advanced kidney disease (AKD). To provide summarised information on their content, use and reported results. To provide an overview of interventions currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Engels, Noel, de Graav, Gretchen N, van der Nat, Paul, van den Dorpel, Marinus, Stiggelbout, Anne M, Bos, Willem Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494569/
https://www.ncbi.nlm.nih.gov/pubmed/36130746
http://dx.doi.org/10.1136/bmjopen-2021-055248
_version_ 1784793821913022464
author Engels, Noel
de Graav, Gretchen N
van der Nat, Paul
van den Dorpel, Marinus
Stiggelbout, Anne M
Bos, Willem Jan
author_facet Engels, Noel
de Graav, Gretchen N
van der Nat, Paul
van den Dorpel, Marinus
Stiggelbout, Anne M
Bos, Willem Jan
author_sort Engels, Noel
collection PubMed
description OBJECTIVES: To provide a comprehensive overview of interventions that support shared decision-making (SDM) for treatment modality decisions in advanced kidney disease (AKD). To provide summarised information on their content, use and reported results. To provide an overview of interventions currently under development or investigation. DESIGN: The JBI methodology for scoping reviews was followed. This review conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist. DATA SOURCES: MEDLINE, Embase, Web of Science, Cochrane Library, Emcare, PsycINFO, PROSPERO and Academic Search Premier for peer-reviewed literature. Other online databases (eg, clinicaltrials.gov, OpenGrey) for grey literature. ELIGIBILITY FOR INCLUSION: Records in English with a study population of patients >18 years of age with an estimated glomerular filtration rate <30 mL/min/1.73 m(2). Records had to be on the subject of SDM, or explicitly mention that the intervention reported on could be used to support SDM for treatment modality decisions in AKD. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened and selected records for data extraction. Interventions were categorised as prognostic tools (PTs), educational programmes (EPs), patient decision aids (PtDAs) or multicomponent initiatives (MIs). Interventions were subsequently categorised based on the decisions they were developed to support. RESULTS: One hundred forty-five interventions were identified in a total of 158 included records: 52 PTs, 51 EPs, 29 PtDAs and 13 MIs. Sixteen (n=16, 11%) were novel interventions currently under investigation. Forty-six (n=46, 35.7%) were reported to have been implemented in clinical practice. Sixty-seven (n=67, 51.9%) were evaluated for their effects on outcomes in the intended users. CONCLUSION: There is no conclusive evidence on which intervention is the most efficacious in supporting SDM for treatment modality decisions in AKD. There is a lot of variation in selected outcomes, and the body of evidence is largely based on observational research. In addition, the effects of these interventions on SDM are under-reported.
format Online
Article
Text
id pubmed-9494569
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-94945692022-09-23 Shared decision-making in advanced kidney disease: a scoping review Engels, Noel de Graav, Gretchen N van der Nat, Paul van den Dorpel, Marinus Stiggelbout, Anne M Bos, Willem Jan BMJ Open Renal Medicine OBJECTIVES: To provide a comprehensive overview of interventions that support shared decision-making (SDM) for treatment modality decisions in advanced kidney disease (AKD). To provide summarised information on their content, use and reported results. To provide an overview of interventions currently under development or investigation. DESIGN: The JBI methodology for scoping reviews was followed. This review conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist. DATA SOURCES: MEDLINE, Embase, Web of Science, Cochrane Library, Emcare, PsycINFO, PROSPERO and Academic Search Premier for peer-reviewed literature. Other online databases (eg, clinicaltrials.gov, OpenGrey) for grey literature. ELIGIBILITY FOR INCLUSION: Records in English with a study population of patients >18 years of age with an estimated glomerular filtration rate <30 mL/min/1.73 m(2). Records had to be on the subject of SDM, or explicitly mention that the intervention reported on could be used to support SDM for treatment modality decisions in AKD. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently screened and selected records for data extraction. Interventions were categorised as prognostic tools (PTs), educational programmes (EPs), patient decision aids (PtDAs) or multicomponent initiatives (MIs). Interventions were subsequently categorised based on the decisions they were developed to support. RESULTS: One hundred forty-five interventions were identified in a total of 158 included records: 52 PTs, 51 EPs, 29 PtDAs and 13 MIs. Sixteen (n=16, 11%) were novel interventions currently under investigation. Forty-six (n=46, 35.7%) were reported to have been implemented in clinical practice. Sixty-seven (n=67, 51.9%) were evaluated for their effects on outcomes in the intended users. CONCLUSION: There is no conclusive evidence on which intervention is the most efficacious in supporting SDM for treatment modality decisions in AKD. There is a lot of variation in selected outcomes, and the body of evidence is largely based on observational research. In addition, the effects of these interventions on SDM are under-reported. BMJ Publishing Group 2022-09-21 /pmc/articles/PMC9494569/ /pubmed/36130746 http://dx.doi.org/10.1136/bmjopen-2021-055248 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Renal Medicine
Engels, Noel
de Graav, Gretchen N
van der Nat, Paul
van den Dorpel, Marinus
Stiggelbout, Anne M
Bos, Willem Jan
Shared decision-making in advanced kidney disease: a scoping review
title Shared decision-making in advanced kidney disease: a scoping review
title_full Shared decision-making in advanced kidney disease: a scoping review
title_fullStr Shared decision-making in advanced kidney disease: a scoping review
title_full_unstemmed Shared decision-making in advanced kidney disease: a scoping review
title_short Shared decision-making in advanced kidney disease: a scoping review
title_sort shared decision-making in advanced kidney disease: a scoping review
topic Renal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494569/
https://www.ncbi.nlm.nih.gov/pubmed/36130746
http://dx.doi.org/10.1136/bmjopen-2021-055248
work_keys_str_mv AT engelsnoel shareddecisionmakinginadvancedkidneydiseaseascopingreview
AT degraavgretchenn shareddecisionmakinginadvancedkidneydiseaseascopingreview
AT vandernatpaul shareddecisionmakinginadvancedkidneydiseaseascopingreview
AT vandendorpelmarinus shareddecisionmakinginadvancedkidneydiseaseascopingreview
AT stiggelboutannem shareddecisionmakinginadvancedkidneydiseaseascopingreview
AT boswillemjan shareddecisionmakinginadvancedkidneydiseaseascopingreview